UGT genomic diversity: beyond gene duplication

被引：117

作者：

Guillemette, Chantal ^{[1
]}

Levesque, Eric

Harvey, Mario

Bellemare, Judith

Menard, Vincent

机构：

[1] CHUQ Res Ctr, Pharmacogen Lab, Canada Res Chair Pharmacogen, Quebec City, PQ G1V 4G2, Canada

来源：

DRUG METABOLISM REVIEWS | 2010年 / 42卷 / 01期

基金：

加拿大自然科学与工程研究理事会; 加拿大健康研究院;

关键词：

HUMAN UDP-GLUCURONOSYLTRANSFERASES; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; MESSENGER-RNA EXPRESSION; ACTIVATED-RECEPTOR-ALPHA; COPY-NUMBER-VARIATION; PREGNANE-X RECEPTOR; HUMAN-LIVER; PROSTATE-CANCER; DELETION POLYMORPHISM; IN-VITRO;

D O I：

10.3109/03602530903210682

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The human uridine diphospho (UDP)-glucuronosyltransferase (UGT) superfamily comprises enzymes responsible for a major biotransformation phase II pathway: the glucuronidation process. The UGT enzymes are located in the endoplasmic reticulum of almost all tissues, where they catalyze the inactivation of several endogenous and exogenous molecules, including bilirubin, sex steroids, numerous prescribed drugs, and environmental toxins. This metabolic pathway is particularly variable. The influence of inheritable polymorphisms in human UGT-encoding genes has been extensively documented and was shown to be responsible for a fraction of the observed phenotypic variability. Other key genomic processes are likely underlying this diversity; these include copy-number variations, epigenetic factors, and newly discovered splicing mechanisms. This review will discuss novel molecular aspects that may be determinant to UGT phenotypes.</.

引用

页码：24 / 44

页数：21

共 134 条

[21]

Czernik PJ, 2000, DRUG METAB DISPOS, V28, P1210

[22] Deep cap analysis gene expression (CAGE): genome-wide identification of promoters, quantification of their expression, and network inference [J].